Floatz logo

Senl_B19 Autologous Car-T Treatment

Refractory Acute Lymphoblastic Leukemia

Peking University People's HospitalCell therapyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

252 Active assets in the Refractory Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Gm-Csf
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs
Fred Hutchinson Cancer Center
Phase 2/3BBB
THIOGUANINE ANHYDROUS
St. Jude Children's Research Hospital
Phase 4BBB
Equine Atg
Instituto Nacional de Cancer, Brazil
Phase 3BBB
MERCAPTOPURINE ANHYDROUS
Dana-Farber Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

Senl_B19 Autologous Car-T Treatment is also rated in:

adult acute lymphoblastic leukemiaDormant
D
Indicative ·
30 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
D
Indicative ·
30 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →